Top Biotechnology Stock Picking: Cerecor Inc. (CERC), Amgen Inc. (AMGN)

Cerecor Inc. (CERC) ended last trading session with a change of -24.99 percent. It trades at an average volume of 288.54K shares versus 2.66M shares recorded at the end of last trading session. The share price of $0.9 is at a distance of 23.3 percent from its 52-week low and down -83.93 percent versus its peak. The company has a market cap of $5.4M and currently has 6M shares outstanding. The share price is currently 13.66 percent versus its SMA20, 4.89 percent versus its SMA50, and -66.26 percent versus its SMA200. The stock has a weekly performance of 21.34 percent and is 2.24 percent year-to-date as of the recent close.

On February 07, 2017 Cerecor Inc. (CERC) announced that it has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value and has engaged SunTrust Robinson Humphrey, Inc. (“SunTrust”) as its exclusive financial advisor for this process. Potential strategic alternatives that may be explored or evaluated as part of this process include an acquisition, merger, business combination or other strategic transaction. The Company has not made a decision to pursue any specific transaction or other strategic alternative, and there can be no assurance that this process will result in any such transaction.

Amgen Inc. (AMGN) recently recorded -0.21 percent change and currently at $181.05 is 37.33 percent away from its 52-week low and down -0.48 percent versus its peak. It has a past 5-day performance of 0.89 percent and trades at an average volume of 3.46M shares. The stock has a 1-month performance of 8.85 percent and is 24.68 percent year-to-date as of the recent close. There were about 736M shares outstanding which made its market cap $133.25B. The share price is currently 3.51 percent versus its SMA20, 10.92 percent versus its SMA50, and 14.32 percent versus its SMA200.

On March 7, 2017 Amgen Inc. (AMGN) announced that its Board of Directors declared a $1.15 per share dividend for the second quarter of 2017. The dividend will be paid on June 8, 2017, to all stockholders of record as of the close of business on May 17, 2017.

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.